The liberal talking point is inaccurate. But there’s a reason it resonates with the public. The 2020 presidential race will pit the Democrats’ “Medicare for All” proposal against the Trump administration’s “Medicare for Less.” At least that’s how the Washington Post and some Democratic political operatives suggest it will play out. According to the Post article, … [Read more...] about ‘Medicare for All’ vs. ‘Medicare for Less’?
Trump Blames the Wrong Government for High Drug Prices
Published on RealClearHealth.com | Medicare-for-All enthusiasts gaze wistfully at government-run health care systems abroad and see much to admire. When it comes to drug prices, the Trump administration seems to share that admiration. The Department of Health and Human Services is preparing to launch a massive demonstration program that would link Medicare reimbursement for … [Read more...] about Trump Blames the Wrong Government for High Drug Prices
Americans are in no mood for another health care upheaval
Published in The Los Angeles Times | PAEONIAN SPRINGS, Va. Conservatives and progressives agree that everyone should be able to get health insurance and have access to quality health care. But the divide over how to accomplish that goal is wide and deep. Progressives believe the government should make decisions about allocation of the resources in our health sector while conservatives … [Read more...] about Americans are in no mood for another health care upheaval
Examination of International Drug Pricing Policies in Selected Countries Shows Prevalent Government Control over Pricing and Restrictions on Access
Report Extract: The Trump Administration has proposed using its demonstration authority under section 1115A of the Social Security Act to test a method of reimbursement for physician-administered drugs based on prices in 14 countries. The proposal is controversial, raising constitutional questions about the agency’s authority to modify Medicare reimbursement absent congressional action, as well … [Read more...] about Examination of International Drug Pricing Policies in Selected Countries Shows Prevalent Government Control over Pricing and Restrictions on Access
A Closer Look At The Drug Rebate Proposal
Last fall, I wrote in Forbes about U.S. based biotechnology manufacturer Amgen announcing it was slashing the list price of its breakthrough cholesterol-lowering drug Repatha by 60% in an effort to improve access and affordability for patients. Too many patients who had been prescribed the drug were walking away from the pharmacy empty handed because of sticker shock over … [Read more...] about A Closer Look At The Drug Rebate Proposal
Rebates And Drug Costs: What The New Proposal Would Mean
The Trump administration is trying in myriad ways to answer demands from consumers for lower prescription drug prices—a topic that got serious attention before the Senate Finance Committee on Tuesday where top executives of seven major drug companies testified. The president announced his “American Patients First” agenda in May, offering nearly 30 policy recommendations to … [Read more...] about Rebates And Drug Costs: What The New Proposal Would Mean
The Costs of Government’s Benevolent Coercion
Critics cried sabotage when political leaders took action to repair some of the damage done by the Affordable Care Act. They saw sinister motives behind the decision by the last Congress to repeal the individual mandate and in Trump administration regulations that made more affordable health insurance options available to individuals and small groups. But a new study by the … [Read more...] about The Costs of Government’s Benevolent Coercion
Do Democrats Want to Roll Back Consumer-Friendly Health Options?
If they said it once, they said it 200 at times. At a recent hearing before the House Energy and Commerce Health subcommittee (live-streamed here), the majority members repeatedly called the new Short Term Limited Duration plan option “Junk Plans.” In my testimony, I talked about the benefits these plans offer to people who are between jobs, young people in the gig economy, early … [Read more...] about Do Democrats Want to Roll Back Consumer-Friendly Health Options?